Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Saved in:
| Title: | Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. |
|---|---|
| Authors: | Paton NI; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Infectious Diseases Translational Research Programme, National University of Singapore, Singapore, Singapore.; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom., Gurumurthy M; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lu Q; Singapore Clinical Research Institute, Singapore, Singapore, Singapore., Leek F; Clinical Imaging Research Centre, National University of Singapore, Singapore, Singapore., Kwan P; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Koh HWL; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Molton J; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Mortera L; Quezon Institute, Quezon City, Philippines., Naval S; Lung Centre of the Philippines, Quezon City, Philippines., Bakar ZA; Institute of Respiratory Medicine, Kuala Lumpur, Malaysia., Pang YK; University of Malaya Medical Centre, Kuala Lumpur, Malaysia., Lum L; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lim TK; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Cross GB; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lekurwale G; Singapore Clinical Research Institute, Singapore, Singapore, Singapore., Choi H; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Au V; Institute of Cellular and Molecular Biology, Singapore, Singapore., Connolly J; Institute of Cellular and Molecular Biology, Singapore, Singapore., Hibberd M; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Department of Microbiology, National University of Singapore, Singapore, Singapore., Green JA; GSK, Greenford, United Kingdom. |
| Corporate Authors: | Pascolizumab Tuberculosis Trial Team |
| Source: | The Journal of infectious diseases [J Infect Dis] 2024 Sep 23; Vol. 230 (3), pp. 590-597. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38527849 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Paton+NI%22">Paton NI</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Infectious Diseases Translational Research Programme, National University of Singapore, Singapore, Singapore.; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gurumurthy+M%22">Gurumurthy M</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Lu+Q%22">Lu Q</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Leek+F%22">Leek F</searchLink>; Clinical Imaging Research Centre, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Kwan+P%22">Kwan P</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Koh+HWL%22">Koh HWL</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Molton+J%22">Molton J</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Mortera+L%22">Mortera L</searchLink>; Quezon Institute, Quezon City, Philippines.<br /><searchLink fieldCode="AU" term="%22Naval+S%22">Naval S</searchLink>; Lung Centre of the Philippines, Quezon City, Philippines.<br /><searchLink fieldCode="AU" term="%22Bakar+ZA%22">Bakar ZA</searchLink>; Institute of Respiratory Medicine, Kuala Lumpur, Malaysia.<br /><searchLink fieldCode="AU" term="%22Pang+YK%22">Pang YK</searchLink>; University of Malaya Medical Centre, Kuala Lumpur, Malaysia.<br /><searchLink fieldCode="AU" term="%22Lum+L%22">Lum L</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Lim+TK%22">Lim TK</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Cross+GB%22">Cross GB</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Lekurwale+G%22">Lekurwale G</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Choi+H%22">Choi H</searchLink>; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Au+V%22">Au V</searchLink>; Institute of Cellular and Molecular Biology, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Connolly+J%22">Connolly J</searchLink>; Institute of Cellular and Molecular Biology, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Hibberd+M%22">Hibberd M</searchLink>; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Department of Microbiology, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Green+JA%22">Green JA</searchLink>; GSK, Greenford, United Kingdom. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22Pascolizumab+Tuberculosis+Trial+Team%22">Pascolizumab Tuberculosis Trial Team</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220413675%22">The Journal of infectious diseases</searchLink> [J Infect Dis] 2024 Sep 23; Vol. 230 (3), pp. 590-597. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0413675 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1537-6613 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200221899%22">00221899 </searchLink><i>NLM ISO Abbreviation: </i>J Infect Dis <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38527849 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/infdis/jiae104 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 590 Titles: – TitleFull: Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Paton NI – PersonEntity: Name: NameFull: Gurumurthy M – PersonEntity: Name: NameFull: Lu Q – PersonEntity: Name: NameFull: Leek F – PersonEntity: Name: NameFull: Kwan P – PersonEntity: Name: NameFull: Koh HWL – PersonEntity: Name: NameFull: Molton J – PersonEntity: Name: NameFull: Mortera L – PersonEntity: Name: NameFull: Naval S – PersonEntity: Name: NameFull: Bakar ZA – PersonEntity: Name: NameFull: Pang YK – PersonEntity: Name: NameFull: Lum L – PersonEntity: Name: NameFull: Lim TK – PersonEntity: Name: NameFull: Cross GB – PersonEntity: Name: NameFull: Lekurwale G – PersonEntity: Name: NameFull: Choi H – PersonEntity: Name: NameFull: Au V – PersonEntity: Name: NameFull: Connolly J – PersonEntity: Name: NameFull: Hibberd M – PersonEntity: Name: NameFull: Green JA IsPartOfRelationships: – BibEntity: Dates: – D: 23 M: 09 Text: 2024 Sep 23 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1537-6613 Numbering: – Type: volume Value: 230 – Type: issue Value: 3 Titles: – TitleFull: The Journal of infectious diseases Type: main |
| ResultId | 1 |
